Join Richmond Pharamcology at the 2nd DIA Cardiac Safety Workshop in Japan for our latest TQT Analysis in Japanese and Caucasian Volunteers

Posted:
16
August 2011

Richmond Pharmacology Ltd is proud to announce its participation in the �2nd DIA Cardiac Safety Workshop in Japan,� being held September 5-6, 2011 at Tower Hall Funabori in Tokyo, Japan. The meeting will address the key scientific, clinical and regulatory issues of implementation of ICH-E14 in Japan and bring together experts from multiple disciplines; intended to facilitate an open and productive dialogue between regulatory, industry and academic delegates.As a feature, the first ever formal Japanese Caucasian bridging TQT analysis will be presented by Dr Jorg Taubel, CEO and Principal Investigator of Richmond Pharmacology Ltd. The analysis was carried out jointly between the Department of Pharmacology of Toho University, the Cardiovascular Sciences Research Centre at St Georges University of London and Richmond Pharmacology Ltd. This groundbreaking presentation being held on Day 1, Session 3 from 17h00 to 17h30 promises to be an informative and insightful discussion relating to the recent implementation of ICH-E14.Having successfully completed in excess of 50 studies in Japanese subjects since 2002, many of which have already been used in regulatory submissions in Japan, Richmond Pharmacology Ltd is well positioned to conduct TQT Studies in Japanese subjects outside of Japan and for the conduct of TQT Bridging Studies in a mixed Japanese and Caucasian study populations. To learn more about our specialist expertise in Japanese Studies come meet our team at booth numbers 8-9, where Richmond Pharmacology Ltd will be happy to discuss our capabilities in more detail.If you are interested in attending the 2nd DIA Cardiac Safety Workshop in Japan, click here to register or contact a member of our business development team to arrange a meeting in person. We look forward to seeing you in Tokyo!

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more